These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 33838946)
1. [Implementation of a new gene therapy in ophthalmology: Regulatory and organizational issues]. Daruich A; Boinet R; Falcou C; Cotteret C; Magassa A; Schlatter J; Escalup R; Cisternino S; Valleix S; Robert MP; Bremond-Gignac D J Fr Ophtalmol; 2021 May; 44(5):730-737. PubMed ID: 33838946 [TBL] [Abstract][Full Text] [Related]
2. Gene discovery and prevalence in inherited retinal dystrophies. Hamel CP C R Biol; 2014 Mar; 337(3):160-6. PubMed ID: 24702842 [TBL] [Abstract][Full Text] [Related]
3. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee. Han J; Joo K; Kim US; Woo SJ; Lee EK; Lee JY; Park TK; Kim SJ; Byeon SH Korean J Ophthalmol; 2023 Apr; 37(2):166-186. PubMed ID: 36950921 [TBL] [Abstract][Full Text] [Related]
4. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.]. Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058 [TBL] [Abstract][Full Text] [Related]
9. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia]. Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591 [TBL] [Abstract][Full Text] [Related]
10. Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date. Padhy SK; Takkar B; Narayanan R; Venkatesh P; Jalali S Appl Clin Genet; 2020; 13():179-208. PubMed ID: 33268999 [TBL] [Abstract][Full Text] [Related]
11. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Viriato D; Bennett N; Sidhu R; Hancock E; Lomax H; Trueman D; MacLaren RE Adv Ther; 2020 Mar; 37(3):1233-1247. PubMed ID: 32034665 [TBL] [Abstract][Full Text] [Related]
12. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Testa F; Bacci G; Falsini B; Iarossi G; Melillo P; Mucciolo DP; Murro V; Salvetti AP; Sodi A; Staurenghi G; Simonelli F Eye (Lond); 2024 Sep; 38(13):2504-2515. PubMed ID: 38627549 [TBL] [Abstract][Full Text] [Related]
13. The first gene therapy for Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119 [TBL] [Abstract][Full Text] [Related]
14. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis. Hussain RM; Tran KD; Maguire AM; Berrocal AM Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202 [TBL] [Abstract][Full Text] [Related]
15. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials. Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102 [TBL] [Abstract][Full Text] [Related]
16. Frequency of Kahraman NS; Öner A; Özkul Y; Dündar M Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537 [TBL] [Abstract][Full Text] [Related]
19. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec. Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237 [TBL] [Abstract][Full Text] [Related]